| Literature DB >> 27256089 |
Rafael Rehwald1, Johannes Petersen1, Alexandra Gratl2, Heinz Zoller3, Andreas Mader1, Alexander Loizides1, Astrid E Grams4, Josef Klocker3, Bernhard Glodny1.
Abstract
OBJECTIVE: Experimental coarctation of the aorta prevents the development of downstream atherosclerosis. The aim of this study was to find out whether or not atherosclerotic stenoses protect distal vascular territories from developing atherosclerosis in humans. DESIGN ANDEntities:
Keywords: RADIOLOGY & IMAGING; arteriosclerosis; peripheral arterial disease; risk factors
Mesh:
Year: 2016 PMID: 27256089 PMCID: PMC4893845 DOI: 10.1136/bmjopen-2015-010704
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Baseline characteristics of the patient group, as well as of the group divided into women and men
| All | Mean±SD | Women | Mean±SD | Men | Mean±SD | |
|---|---|---|---|---|---|---|
| N | 101 (100%) | – | 31 (30.7%) | – | 70 (69.3%) | – |
| Legs | 202 (100%) | – | 62 (30.7%) | – | 140 (69.3%) | – |
| Age | 38–91 | 66.1±10.8 | 46–89 | 69.7±10.8 | 38–91 | 64.5±10.5 |
| BMI | 15.8–41.1 | 25.8±4.7 | 15.8–41.1 | 24.6±5.2 | 16.6–39.9 | 25.9±4.4 |
| BP syst. | 113–190 | 154.8±18.9 | 113–185 | 153.2±18.5 | 117–190 | 155.5±19.2 |
| BP diast. | 50–109 | 80.7±11.2 | 50–105 | 79.0±11.5 | 57–109 | 81.5±11.2 |
| DM | ||||||
| Y | 28 (27.7%) | – | 10 (32.3%) | – | 18 (25.7%) | – |
| N | 73 (72.3%) | 21 (67.7%) | 52 (74.3%) | |||
| CKD | ||||||
| Y | 20 (19.8%) | – | 8 (25.8%) | – | 12 (12.1%) | – |
| N | 81 (80.2%) | 23 (74.2%) | 58 (82.9%) | |||
| Control | ||||||
| Y | 86 (85.1%) | – | 27 (87.1%) | – | 59 (84.3%) | – |
| N | 11 (10.9%) | 2 (6.5%) | 9 (12.9%) | |||
| NA | 4 (4.0%) | 2 (6.5%) | 2 (2.9%) | |||
| Major amputation | ||||||
| Y | 7 (6.9%) | – | 4 (12.9%) | – | 3 (4.3%) | – |
| N | 94 (93.1%) | (87.1%) | (95.7%) | |||
| Deceased | ||||||
| Y | 10 (9.9%) | – | 4 (12.9%) | – | 6 (8.6%) | – |
| N | 91 (90.1%) | 27 (87.1%) | 64 (91.4%) | |||
| OAC | ||||||
| Y | 17 (16.8%) | – | 6 (19.4%) | – | 11 (15.7%) | – |
| N | 84 (83.2%) | 25 (80.6%) | 59 (84.3%) | |||
| HMG-CoA RI | ||||||
| Y | 85 (84.2%) | – | 22 (71.0%) | – | 63 (90.0%) | – |
| N | 16 (15.8%) | 9 (29.0%) | 7 (10.0%) | |||
| APD | ||||||
| Y | 91 (90.1%) | – | 28 (90.3%) | – | 63 (90.0%) | – |
| N | 10 (9.9%) | 3 (9.7%) | 7 (10.0%) | |||
| Smoker | ||||||
| Y | 64 (63.4%) | – | 17 (54.8%) | – | 47 (67.1%) | – |
| N | 37 (36.6%) | 14 (45.2%) | 23 (32.9%) | |||
| Arterial hypertension | ||||||
| Y | 76 (75.2%) | – | 28 (90.3%) | – | 48 (68.6%) | – |
| N | 25 (24.8%) | 3 (9.7%) | 22 (31.4%) | |||
| Fontaine stages | ||||||
| 1 | 2 (2.0%) | – | 1 (3.2%) | – | 1 (1.4%) | – |
| 2 | 62 (61.4%) | – | 17 (54.8%) | – | 45 (64.3%) | – |
| 3 | 16 (15.8%) | – | 7 (22.6%) | – | 9 (12.9%) | – |
| 4 | 21 (20.8%) | – | 6 (19.4%) | – | 15 (21.4%) | – |
| Collaterals | ||||||
| Iliac arteries | 404 (100%) | – | 124 (100%) | – | 280 (100%) | – |
| 0 | 339 (83.9%) | – | 109 (87.9) | – | 230 (82.1%) | – |
| 1 | 11 (2.7%) | – | 0 (0.0%) | – | 11 (3.9%) | – |
| 2 | 12 (3.0%) | – | 5 (4.0%) | – | 7 (2.5%) | – |
| 3 | 19 (4.7%) | – | 5 (4.0%) | – | 14 (5.0%) | – |
| 4 | 21 (5.2%) | – | 5 (4.0%) | – | 16 (5.7%) | – |
| 5 | 2 (0.5%) | – | 0 (0.0%) | – | 2 (0.7%) | – |
| Femoropopliteal arteries | 1084 (100%) | – | 316 (100%) | – | 768 (100%) | – |
| 0 | 929 (85.7%) | – | 258 (81.6%) | – | 671 (87.4%) | – |
| 1 | 11 (1.0%) | – | 5 (1.6%) | – | 6 (0.8%) | – |
| 2 | 26 (2.4%) | – | 14 (4.4) | – | 12 (1.6%) | – |
| 3 | 53 (4.9%) | – | 15 (4.7%) | – | 38 (4.9%) | – |
| 4 | 33 (3.0%) | – | 14 (4.4) | – | 19 (2.5%) | – |
| 5 | 32 (3.0%) | – | 10 (3.2) | – | 22 (2.9%) | – |
| Infragenual arteries | 637 (100%) | – | 175 (100%) | – | 462 (100%) | – |
| 0 | 526 (82.6%) | – | 143 (81.7%) | – | 383 (82.9%) | – |
| 1 | 52 (8.2%) | – | 14 (8.0%) | – | 38 (8.2%) | – |
| 2 | 31 (4.9%) | – | 11 (6.3%) | – | 20 (4.3%) | – |
| 3 | 20 (3.1%) | – | 5 (2.9%) | – | 15 (3.2%) | – |
| 4 | 8 (1.3%) | – | 2 (1.1%) | – | 6 (1.3%) | – |
| 5 | 0 (0.0%) | – | 0 (0.0%) | – | 0 (0.0%) | – |
APD, antiplatelet drug; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; N, no.; OAC, oral anticoagulation; RI, (HMG-CoA-) reductase inhibitor; Y, yes.
Absolute and relative numbers of stenoses within the arbitrarily stated ranges of degree in the respective arterial segments; numbers of Friesinger scores and degrees of calcification
| Vessel | N | Degree of stenosis (NASCET) | Friesinger score (0–5) | Degree of calcification (0–5) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30–50% | 50–70% | 70–90% | ≥90% | 0 | 1 | 2 | 3 | 4 | 5 | 0 | 1 | 2 | 3 | 4 | 5 | ||
| CIA | 202 | 86 | 47 | 27 | 14 | 26 | 87 | 52 | 7 | 17 | 13 | 37 | 40 | 44 | 43 | 24 | 14 |
| 42.6% | 23.3% | 13.4% | 6.9% | 12.9% | 43.1% | 25.7% | 3.5% | 8.4% | 6.4% | 18.3% | 19.8% | 21.8% | 21.3% | 11.9% | 6.9% | ||
| EIA | 202 | 72 | 49 | 24 | 9 | 26 | 87 | 52 | 7 | 17 | 13 | 78 | 50 | 26 | 25 | 19 | 4 |
| 35.6% | 24.3% | 11.9% | 4.5% | 12.9% | 43.1% | 25.7% | 3.5% | 8.4% | 6.4% | 38.6% | 24.8% | 12.9% | 12.4% | 9.4% | 2.0% | ||
| IIA | 202 | 82 | 60 | 43 | 27 | 49 | 75 | 34 | 1 | 18 | 25 | 81 | 49 | 35 | 17 | 15 | 5 |
| 40.6% | 29.7% | 21.3% | 13.4% | 24.3% | 37.1% | 16.8% | 0.5% | 8.9% | 12.4% | 40.1% | 24.3% | 17.3% | 8.4% | 7.4% | 2.5% | ||
| CFA | 201 | 36 | 17 | 8 | 2 | 64 | 102 | 26 | 1 | 6 | 2 | 81 | 57 | 35 | 19 | 6 | 3 |
| 17.9% | 8.5% | 4.0% | 1.0% | 31.8% | 50.7% | 12.9% | 0.5% | 3.0% | 1.0% | 40.3% | 28.4% | 17.4% | 9.5% | 3.0% | 1.5% | ||
| DFA | 195 | 20 | 9 | 3 | 2 | 107 | 70 | 14 | 1 | 1 | 2 | 120 | 42 | 22 | 7 | 2 | 2 |
| 10.3% | 4.6% | 1.5% | 1.0% | 54.9% | 35.9% | 7.2% | 0.5% | 0.5% | 1.0% | 61.5% | 21.5% | 11.3% | 3.6% | 1.0% | 1.0% | ||
| SFA | 192 | 108 | 87 | 73 | 44 | 50 | 33 | 19 | 19 | 23 | 48 | 60 | 21 | 21 | 33 | 22 | 35 |
| 56.3% | 45.3% | 38.0% | 22.9% | 26.0% | 17.2% | 9.9% | 9.9% | 12.0% | 25.0% | 31.3% | 10.9% | 10.9% | 17.2% | 11.5% | 18.2% | ||
| PI | 166 | 48 | 30 | 25 | 22 | 61 | 56 | 24 | 1 | 3 | 21 | 73 | 38 | 18 | 46 | 8 | 13 |
| 28.9% | 18.1% | 15.1% | 13.3% | 36.7% | 33.7% | 14.5% | 0.6% | 1.8% | 12.7% | 44.0% | 22.9% | 10.8% | 9.6% | 4.8% | 7.8% | ||
| PII | 168 | 34 | 25 | 22 | 21 | 75 | 57 | 11 | 2 | 1 | 22 | 87 | 37 | 19 | 10 | 4 | 11 |
| 20.2% | 14.9% | 13.1% | 12.5% | 44.6% | 33.9% | 6.5% | 1.2% | 0.6% | 13.1% | 43.1% | 18.3% | 9.4% | 5.0% | 2.0% | 5.4% | ||
| PIII | 162 | 29 | 21 | 18 | 17 | 104 | 30 | 7 | 0 | 2 | 19 | 109 | 28 | 8 | 6 | 2 | 9 |
| 17.9% | 13.0% | 11.1% | 10.5% | 64.2% | 18.5% | 4.3% | 0.0% | 1.2% | 11.7% | 67.3% | 17.3% | 4.9% | 3.7% | 1.2% | 5.6% | ||
| TFT | 150 | 26 | 19 | 15 | 15 | 92 | 31 | 8 | 2 | 1 | 16 | 105 | 18 | 9 | 5 | 3 | 10 |
| 17.3% | 12.7% | 10.0% | 10.0% | 61.3% | 20.7% | 5.3% | 1.3% | 0.7% | 10.7% | 70.0% | 12.0% | 6.0% | 3.3% | 2.0% | 6.7% | ||
| ATA | 166 | 58 | 48 | 44 | 33 | 86 | 24 | 8 | 3 | 6 | 39 | 114 | 16 | 5 | 9 | 9 | 13 |
| 34.9% | 28.9% | 26.5% | 19.9% | 51.8% | 14.5% | 4.8% | 1.8% | 3.6% | 23.5% | 68.7% | 9.6% | 3.0% | 5.4% | 5.4% | 7.8% | ||
| PTA | 157 | 53 | 50 | 47 | 36 | 79 | 27 | 3 | 1 | 3 | 44 | 102 | 22 | 10 | 4 | 5 | 14 |
| 33.8% | 31.8% | 29.9% | 22.9% | 50.3% | 17.2% | 1.9% | 0.6% | 1.9% | 28.0% | 65.0% | 14.0% | 6.4% | 2.5% | 3.2% | 8.9% | ||
| FA | 164 | 33 | 28 | 24 | 23 | 85 | 40 | 8 | 0 | 0 | 31 | 113 | 22 | 16 | 3 | 2 | 8 |
| 20.1% | 17.1% | 14.6% | 14.0% | 51.8% | 24.4% | 4.9% | 0.0% | 0.0% | 18.9% | 68.9% | 13.4% | 9.8% | 1.8% | 1.2% | 4.9% | ||
ATA, anterior tibial artery; CFA, common femoral artery; CIA, common iliac artery; DFA, deep femoral artery; EIA, external iliac artery; FA, fibular artery; IIA, internal iliac artery; PI, PII and PIII, popliteal artery segment I, II or III; PTA, posterior tibial artery; SFA, superficial femoral artery; TFT, tibiofibular trunk.
Significance levels of all tests of the differences between the segments in relation to the respective classification level
| Difference | NASCET | EIA | IIA | CFA | DFA | SFA | PI | PII | PIII | TFT | ATA | PTA | FA | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | N | F | C | ||
| CIA | 30–49% | n | y | n | n | n | n | n | n | n | n | n | n | y | y | y | y | y | n | y | y | y | y | y | n | y | y | y | n | n | n | y | n | n | n | n | n |
| 50–69% | y | n | n | n | n | n | n | n | n | y | y | y | y | y | y | y | y | n | y | y | y | y | y | y | y | y | y | n | n | n | n | n | y | n | n | n | |
| 70–89% | y | n | n | n | n | n | n | n | n | y | y | y | y | y | y | y | y | n | y | y | n | y | y | y | n | y | y | n | n | y | y | n | y | n | n | y | |
| ≥90 | y | n | n | n | n | n | n | n | n | y | n | n | n | y | y | n | n | n | y | n | n | y | n | n | n | n | n | n | n | n | n | n | y | n | n | y | |
| EIA | 30–49% | n | n | n | y | y | y | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | |||
| 50–69% | n | n | n | y | n | n | n | n | n | n | n | n | n | n | y | n | y | n | n | n | y | n | n | n | n | n | y | n | n | n | n | n | n | ||||
| 70–89% | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | y | y | n | ||||
| ≥90 | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | ||||
| IIA | 30–49% | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | ||||||
| 50–69% | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | |||||||
| 70–89% | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | |||||||
| ≥90 | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | |||||||
| CFA | 30–49% | n | n | n | y | y | y | n | n | n | n | y | n | n | y | n | n | n | n | y | n | n | n | n | n | n | n | n | |||||||||
| 50–69% | n | n | n | y | y | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | ||||||||||
| 70–89% | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | ||||||||||
| ≥90 | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | n | ||||||||||
| DFA | 30–49% | y | y | n | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | n | n | y | n | ||||||||||||
| 50–69% | y | y | n | y | y | n | y | y | n | n | y | n | y | y | n | y | y | y | n | n | n | n | y | n | |||||||||||||
| 70–89% | n | n | y | n | n | n | y | y | n | n | y | n | y | y | n | y | y | y | n | n | n | n | y | n | |||||||||||||
| ≥90 | n | n | n | n | n | n | n | n | n | y | n | n | y | n | n | n | n | y | n | n | n | y | y | y | |||||||||||||
| SFA | 30–49% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | n | y | y | |||||||||||||||
| 50–69% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | n | y | y | y | n | y | y | ||||||||||||||||
| 70–89% | y | y | y | y | y | y | y | y | n | n | y | y | y | y | n | y | n | n | n | n | n | ||||||||||||||||
| ≥90 | y | y | y | y | y | y | y | y | n | y | y | n | y | y | n | y | n | n | n | n | n | ||||||||||||||||
| PI | 30–49% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | ||||||||||||||||||
| 50–69% | y | y | y | y | y | y | y | y | y | y | y | n | y | y | y | y | y | y | |||||||||||||||||||
| 70–89% | y | y | y | y | y | y | y | y | n | y | y | n | y | y | y | n | n | n | |||||||||||||||||||
| ≥90 | y | y | y | y | y | y | y | y | y | y | y | n | y | y | y | y | n | n | |||||||||||||||||||
| PII | 30–49% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | |||||||||||||||||||||
| 50–69% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | y | ||||||||||||||||||||||
| 70–89% | y | y | y | y | y | y | y | y | y | y | y | y | y | y | n | ||||||||||||||||||||||
| ≥90 | y | y | y | y | y | y | y | y | y | y | y | y | y | y | n | ||||||||||||||||||||||
| PIII | 30–49% | y | y | y | y | y | y | y | y | y | n | y | y | ||||||||||||||||||||||||
| 50–69% | y | y | y | y | y | n | y | y | y | n | y | n | |||||||||||||||||||||||||
| 70–89% | y | y | y | y | y | n | y | y | y | y | y | n | |||||||||||||||||||||||||
| ≥90 | y | y | y | y | y | y | y | y | y | y | y | n | |||||||||||||||||||||||||
| TFT | 30–49% | y | y | y | y | y | y | y | y | y | |||||||||||||||||||||||||||
| 50–69% | y | y | y | y | y | y | y | y | y | ||||||||||||||||||||||||||||
| 70–89% | y | y | y | y | y | y | y | y | y | ||||||||||||||||||||||||||||
| ≥90 | y | y | y | y | y | y | y | y | y | ||||||||||||||||||||||||||||
The effects are most pronounced for stenoses of the common iliac artery and the superficial femoral artery. No effects of stenoses of the internal iliac arteries, representing a segment without further distant distal depending territories as a virtual internal control.
ATA, anterior tibial artery; C, calcification; CFA, common femoral artery; CIA, common iliac artery; DFA, deep femoral artery; EIA, external iliac artery; F, Friesinger score; FA, fibular artery; IIA, internal iliac artery; N, NASCET; PI, PII and PIII, popliteal artery segment I. II or III; PTA, posterior tibial artery; SFA, superficial femoral artery; TFT, tibiofibular trunk; y, yes, significant.
Figure 1Association of stenoses of pelvic vessels (CIA/EIA/CFA) 30–49%; 50–69%, 70–89% or 90–100% with the extent of the degrees of stenosis distal to them as a percentage comparison with (A) the contralateral side, (B) calcifications and (C) the Friesinger scores. Lower degrees of atherosclerotic burdens distal to stenoses of arteries of the pelvic level are striking. CFA, common femoral artery; CIA, common iliac artery; EIA, external iliac artery.
Figure 2Standardized coefficients of the independent risk factors identified on the regression models with respect to the degree of maximum stenosis at the pelvic level, the femoropopliteal region and the crural region. The degree of stenosis in the pelvis was found to be an independent protective factor of the femoropopliteal region with respect to atherosclerosis. BMI, body mass index; BP, blood pressure; FA, fibular artery; PI, popliteal artery segment I; PTA, posterior tibial artery; PWI, pulse wave index; SFA, superficial femoral artery; TFT, tibiofibular trunk.